

Appl. No.  
Filed



:  
:

unknown  
herewith



Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: October 18, 2001

By: Che S. Chereskin

Che Swyden Chereskin  
Registration No. 41,466  
Agent of Record  
620 Newport Center Drive  
Sixteenth Floor  
Newport Beach, CA 92660  
(949) 760-0404

1045106-10101

Appl. No. : unknown  
Filed : herewith

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Claims 9-11, 14 and 18 have been amended as follows:

Claim 9. (Amended) ~~Use of~~ A method of suppressing formation of memory cells of the immune system of a mammal in need thereof, comprising administering IL-15 inhibiting or eliminating compounds for the manufacture of a pharmaceutical composition for manipulating memory cells of the immune system to the mammal.

Claim 10. (Amended) ~~Use of IL-15 inhibiting or eliminating compounds~~ A method according to claim 9 wherein the memory cells are CD4<sup>+</sup> T lymphocytes.

Claim 11. (Amended) ~~Use of IL-15 inhibiting or eliminating compounds~~ A method according to claim 9 ~~or 10~~ wherein said compound is selected from the group consisting of an anti-IL-15 antibody, anti-IL-15R $\alpha$  antibody, fragments of these antibodies, ~~e.g. the Fab or F(ab')<sub>2</sub> fragment,~~ soluble IL-15R $\alpha$ , fusion proteins ~~consisting of~~ comprising soluble IL-15R $\alpha$  and Fc fragment, compounds, ~~e.g. peptides,~~ binding and/or inhibiting functional IL-15 receptor, IL-15 antisense oligonucleotides.

Claim 14. (Amended) ~~Pharmaceutical composition~~ A method according to claim ~~12 or 13~~ 9 for use in the treatment of auto-immune diseases or in treatment before, during or after transplantation.

Claim 18. (Amended) ~~Pharmaceutical composition~~ A method according to claim ~~16-9~~ 9 for use in the treatment of immune deficiency diseases or in treatment before, during or after vaccination.